title: CSF levels of Aβ1-38/Aβ1-40/Aβ1-42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer's disease.
abstract: Primary progressive aphasia (PPA) is a cognitive syndrome characterized by progressive and isolated language impairments due to neurodegenerative diseases. Recently, an international group of experts published a Consensus Classification of the three PPA clinical variants (naPPA, svPPA and lvPPA). We analyzed 24 patients with PPA by cognitive functions, neuroimaging (MRI, (99 m)Tc ECD-SPECT, (11)C PiB-PET and FDG-PET) and cerebrospinal fluid (CSF) analysis (ptau-181, Aβ1-42, Aβ1-40 and Aβ1-38), to elucidate relationships between neuroimaging studies and biochemical findings in the three PPA clinical variants. Cognitive and speech functions were measured by mini-mental state examination and standard language test of aphasia. The patients with lvPPA showed significant decreases in CSF Aβ1-42 and ratios of Aβ1-42/Aβ1-40 and Aβ1-42/Aβ1-38, and significant increases in CSF ptau-181 and ratios of ptau-181/Aβ1-42 and ptau-181/Aβ1-38; these findings were similar to those of patients with Alzheimer's disease (AD). We observed a higher frequency of the ApoE ε4 allele in the lvPPA patients relative to the two other PPA variants. In (11)C PiB-PET of lvPPA patients, PiB positive findings were detected in cortices of frontal, temporal and parietal lobes and the posterior cingulate, where massive Aβ may accumulate due to AD. Our results of AD-CSF markers including Aβ1-38 and (11)C PiB-PET in the lvPPA patients demonstrate a common pathological mechanism with the occurrence of AD.
authors.affiliation: Departments of Neurology, Gunma University Graduate School of Medicine , Maebashi, Gunma , Japan .
authors.forename: Masaki
authors.initials: M
authors.lastname: Ikeda
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Tashiro
authors.forename: Eriko
authors.initials: E
authors.lastname: Takai
authors.forename: Sachiko
authors.initials: S
authors.lastname: Kurose
authors.forename: Naoko
authors.initials: N
authors.lastname: Fugami
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Tsuda
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Arisaka
authors.forename: Sayaka
authors.initials: S
authors.lastname: Kodaira
authors.forename: Yukio
authors.initials: Y
authors.lastname: Fujita
authors.forename: Kouki
authors.initials: K
authors.lastname: Makioka
authors.forename: Yuji
authors.initials: Y
authors.lastname: Mizuno
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Shimada
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Harigaya
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Takatama
authors.forename: Masakuni
authors.initials: M
authors.lastname: Amari
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Haruyasu
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Higuchi
authors.forename: Koichi
authors.initials: K
authors.lastname: Okamoto
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tsushima
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000000981:diagnostic imaging / Q000235:genetics; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D018888:Aphasia, Primary Progressive / Q000134:cerebrospinal fluid* / Q000000981:diagnostic imaging / Q000235:genetics; D001057:Apolipoproteins E / Q000235:genetics; D015415:Biomarkers / Q000134:cerebrospinal fluid; D006801:Humans; D007807:Language Tests; D049268:Positron-Emission Tomography
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D015415:Biomarkers
keywords: 11C PiB-PET; Alzheimer’s disease; amyloid β protein; cerebrospinal fluid; primary progressive aphasia